GTC Biotherapeutics (fka GTCB)

[floblu14]

>Let companies like MRK and Roche (MAXY’s partner) experiment with tweaking their compounds—that’s their only chance to add value. GTC does not need to take those kinds of risks and probably won’t.<

Is this "tweaking"?? (GTC Patent application from August 7, 06) -
0001] The present invention relates to the recombinant production of an agonistic anti-CD137 antibody and variants thereof. In particular, the current invention provides for the transgenic production of anti-CD137 antibodies, in which the glycosylation profiles of the antibodies are "altered" to enhance their use in the treatment of specific types of cancers or other disease states.
http://www.freshpatents.com/Anti-cd137-antibody-as-an-agent-in-the-treatment-of-cancer-and-glycosyla...

---